Recent Publications by CFE Educators
Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
How I Approach Hepatocellular Adenomas in Hormonally Distinct Populations: Time to Think Outside the (Contraceptive Pill) Box.
2023
Authors: Wang M, Cedars MI, Mehta N, Sarkar M
Policies to Support Lactation at Highly Ranked US Medical Schools.
2023
Authors: Santhosh L, Vo A, Wick C, Mourad M, Sarkar U, Jagsi R, Mangurian C
A SLOWER HUMAN CHORIONIC GONADOTROPIN (HCG) RISE IN EARLY PREGNANCY WAS NOT ASSOCIATED WITH THE DEVELOPMENT OF ABNORMAL PLACENTATION IN PATIENTS WHO CONCEIVED USING ASSISTED REPRODUCTIVE TECHNOLOGY.
2023
Authors: Chantal Durgana, David Huang, Jennifer Qin, Rebecca Wong, Amanda Adeleye, Lydia Zablotska, Marcelle I. Cedars
356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
2023
Authors: S. Gottipati, H.M. Earl, C. Yau, D.A. Cameron, J. Abraham, L. Hayward, F. Reyal, M. Osdoit, G.S. Sonke, J. Wesseling, J. Boughey, M.P. Goetz, A. DeMichele, L. Pusztai, P. Sharma, M. Martin Jimenez, S. Lopez-Tarruella Cobo, M. Del Monte-Millan, F. Symmans, R. Mukhtar
Authorship equity in global health research: who gets the credit at University of California, San Francisco?
2023
Authors: Kaufman R, Fair E, Reid M, Mirzazadeh A
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis.
2023
Authors: Deodhar A, Marzo-Ortega H, Wu J, Wang C, Dina O, Kanik KS, Fallon L, Gensler LS
OBJECTIVE
To evaluate the efficacy and safety of tofacitinib in patients with ankylosing spondylitis (AS) by prior biologic disease-modifying antirheumatic drug (bDMARD) use.
METHODS
Data from a placebo-controlled, double-blind study of patients with active AS were analyzed. Patients received tofacitinib 5 mg twice daily (BID) or placebo to week 16; all received open-label tofacitinib 5 mg BID to week 48 and were stratified by prior treatment (bDMARD-naive or tumor necrosis factor inhibitor [TNFi]-inadequate responder [IR], including bDMARD-experienced [non-IR]). Disease activity/safety were assessed throughout.
RESULTS
Of 269 patients, 207 (77%) were bDMARD-naive; 62 (23%) were in the TNFi-IR subgroup. TNFi-IR patients had higher baseline BMI (28.0 vs. 26.1 kg/m ), longer symptom duration (14.4 vs. 13.2 years), and lower concomitant conventional synthetic DMARD use (14.5% vs. 30.9%) than bDMARD-naive patients. At week 16, for most outcomes, tofacitinib efficacy exceeded placebo for both subgroups and was sustained to week 48. At week 16, tofacitinib versus placebo differences were similar between bDMARD-naive and TNFi-IR patients (Assessment in Spondyloarthritis international Society 40 treatment difference [95% confidence interval]: 30.8% [19.1%-42.6%] vs. 19.4% [1.7%-37.0%]). Adverse event (AE) proportions were similar between tofacitinib-treated bDMARD-naive/TNFi-IR patients (77.5%/77.4%) at week 48 with no deaths. A numerically higher proportion of tofacitinib-treated TNFi-IR versus bDMARD-naive patients discontinued study drug (12.9% vs. 3.9%) or dose reduced/temporarily discontinued due to AEs (19.4% vs. 11.8%).
CONCLUSION
Tofacitinib efficacy exceeded placebo at week 16 for bDMARD-naive/TNFi-IR patients and was sustained to week 48. The absolute magnitude of responses was generally greater in bDMARD-naive patients versus TNFi-IR patients. More TNFi-IR versus bDMARD-naive patients discontinued or dose reduced/temporarily discontinued tofacitinib due to AEs. Small sample size and sample size differences between subgroups limited the interpretation.
View on PubMedErratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
2023
Authors: Rothschild HT, Jo Chien A, Jankowitz RC, Magbanua MJ, Mouabbi JA, Shatsky RA, Levine J, Mukhtar RA
[This corrects the article DOI: 10.1017/cts.2023.142.].
View on PubMedEye on the Prize: Patient Outcomes Research in Medical Education.
2023
Authors: Cooper AZ, Jain S, Santhosh L, Carlos WG
Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures: Clinical Trial Update.
2023
Authors: Ghaffar U, Terlecki R, Yoo JJ, Breyer BN
Real-World Complications of the SpaceOARTM Hydrogel Spacer: A Review of the Manufacturer and User Facility Device Experience Database.
2023
Authors: Fernandez A, Jones CP, Patel HV, Ghaffar U, Hakam N, Li K, Nabavizadeh B, Breyer BN
